Sun Pharma.Inds.
Sun Pharma.Inds. Q1 FY27 earnings call: Revenue & Margins
Q1 FY27 earnings call: what management said on revenue and margins.
What the Q1 FY27 call signalled
0 of 2 strong
The short version
The company expects high single-digit revenue growth for the full year FY27, despite Q1 growth of about 11% (Page 10). The company expects to stick to high single-digit overall revenue growth guidance for FY27 despite Q1 showing ~11% growth.
From Sun Pharma.Inds.'s Q1 FY27 earnings-call transcript · updated 23 Sept 2026.
Revenue & Sales Performance
- The company expects high single-digit revenue growth for the full year FY27, despite Q1 growth of about 11% (Page 10).
- Growth is driven by volume and new product introductions: in domestic market, 60% of growth comes from volume and new prescriptions (Page 20).
- Innovative medicines, both in the U.S. and international markets, continue to show healthy growth and new launches like Unloxcyt and Leqselvi are expected to gain traction over time (Pages 16, 20).
- Domestic business growth is broad-based across all therapy areas, supported by prescription growth and field force expansion especially in tier 2 and 3 cities (Pages 15, 20).
2 more points from Sun Pharma.Inds.'s call on revenue
Pro opens every point from 15K+ earnings calls
Profitability & Margins
See what Sun Pharma.Inds. said on profitability & margins — free account, 30 seconds.
Sun Pharma.Inds. — Quarterly revenue & net profit
Q1 FY27 figures are not in this chart yet. Latest shown: Mar 2026 (Q4 FY26). The Q1 FY27 numbers from the filing are in the analysis on this page.
Reported quarterly figures (₹ Cr). Latest (Q4 FY26): revenue ₹14.6K Cr, net profit ₹2.7K Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Sun Pharma.Inds.'s management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Trident Lifeline (Q1 FY27)
Q1 FY26: ₹23.6 crores . Key investor presentation takeaways from Trident Lifeline Ltd's Q1 FY27 investor presentation — and how it ranks against sector peers.
- KRM Ayurveda (Q1 FY27)
Total income for Q1 FY27: ₹3,286.55 Lakhs, +32.4% YoY . Key investor presentation takeaways from KRM Ayurveda Ltd's Q1 FY27 investor presentation — and how it r
- Balaxi Pharmaceuticals Ltd (Q1 FY27)
Q1 FY27 Revenue: ₹80.68 crore, up 14.1% YoY from ₹70.74 crore in Q1 FY26 (Page 20). Key investor presentation takeaways from Balaxi Pharma's Q1 FY27 investor pr
- Sanjivani Paranteral Ltd (Q1 FY27)
Q1 FY27 consolidated revenue from operations: ₹238.39 Mn, up 33.8% YoY from ₹178.92 Mn in Q1 FY26 (Page 25). Key investor presentation takeaways from Sanjivani
Arthneeti Pro · Annual
Sun Pharma.Inds. and 15K+ more earnings calls,
for less than your morning chai
a day
Every earnings call, ranking and concall Q&A across all four results seasons.
Secure Razorpay payment · instant access
Frequently Asked Questions
What were Sun Pharma.Inds. Q1 FY27 results?
The company expects high single-digit revenue growth for the full year FY27, despite Q1 growth of about 11% (Page 10). The company expects to stick to high single-digit overall revenue growth guidance for FY27 despite Q1 showing ~11% growth.
What is Sun Pharma.Inds. share price analysis?
Sun Pharma.Inds. currently shows a below-average growth signal. The stock trades at a P/E of 34.9 with a market cap of ₹440,830 Cr. Investors should review the full earnings analysis for detailed insights.
Is Sun Pharma.Inds. planning capital expenditure?
The transcript does not explicitly mention any current or future capital expenditure (capex) or strategic capital investments in detail.
Keep Sun Pharma.Inds. on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and the company's earnings call transcript. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.